<DOC>
	<DOCNO>NCT01388738</DOCNO>
	<brief_summary>Ischemic stroke ( IS ) cause high mortality severe disability . To improve outcome 's important choose right way management patient appropriate drug . There large number so-called neuroprotective drug , effective laboratory , n't show positive result clinical study use traditional clinical scale score primary outcome measure . Specialists suggest , investigator could receive good result investigator change design study , particularly investigator select precise sensitive method assessment . Aim study : determine role navigate brain stimulation ( NBS ) evaluation change motor center motor tract administration different cerebroprotective drug . ( The substance wo n't compare ) .</brief_summary>
	<brief_title>Navigation Brain Stimulation Evaluation Neuroprotective Drug Efficiency Patients After Ischemic Stroke .</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Cerebrolysin</mesh_term>
	<mesh_term>Neuroprotective Agents</mesh_term>
	<mesh_term>Cytidine Diphosphate Choline</mesh_term>
	<criteria>patient 3 6 month ischemic stroke hemispheric infarction paresis 2 4 score Medical Research Council Weakness Scale ( MRC ) history seizure pregnancy , lactation cognitive deficiency ( poor compliance ) acute renal failure acute hepatic failure oncological history cardiac pacemaker metal implant regular intake nootropic drug Modified Ashford Scale score 3 regular intake anticonvulsant , neuromuscular relaxant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Navigation Brain Stimulation ( NEXSTIM )</keyword>
	<keyword>cerebroprotective drug effectiveness</keyword>
	<keyword>acute ischemic stroke</keyword>
</DOC>